Issue Date: April 25, 2011
Ipsen Licenses Prostate Cancer Drug
Paris-based Ipsen will pay $35 million up front for the right to codevelop Active Biotech’s prostate cancer compound tasquinimod outside of the Americas and Japan. Active Biotech could score up to $285 million in milestone payments as the drug candidate progresses toward the market. Tasquinimod is in a Phase III trial involving men with metastatic castrate-resistant prostate cancer. Ipsen says the compound will complement its oncology portfolio.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society